Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
'We started 2025 with strong momentum and a focus on generating impactful clinical data across our in vivo gene editing pipeline. Early this year, data from the OTC-HOPE trial provided the first clinical validation for ARCUS in vivo gene insertion following a complete response in an infant with OTC-deficiency,' said Michael Amoroso, Chief Executive Officer of Precision BioSciences. 'In addition, the Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV, our lead program for chronic Hepatitis B, is progressing as planned. We presented encouraging data at the recent EASL Congress highlighting the safety of PBGENE-HBV after repeat dosing as planned in the ELIMINATE-B protocol. We look forward to sharing additional updates from the ELIMINATE-B trial throughout 2025, including antiviral efficacy data from each cohort upon completion of three dose administrations. In addition, we recently received U.S. investigational new drug (IND) approval to expand this important global trial as well as Fast Track Designation from the U.S. Food and Drug Administration (FDA) underscoring ARCUS' potential to deliver a curative treatment option for people in need living with chronic Hepatitis B.'
'In tandem with the ongoing clinical trials, we continued to advance our in vivo gene editing programs and shared encouraging data across multiple assets at ASGCT. Of note, we presented exciting proof of concept data from PBGENE-DMD. This data was the first pre-clinical proof of protein expression linked to improved and sustained muscle function across 3-, 6-, and 9-month time points in disease models. PBGENE-DMD makes a correction in the body's dystrophin gene to produce a near full length functional dystrophin that is present in nature. Due to its targeting of satellite muscle stem cells which are the progenitor cells for new muscle cells, PBGENE-DMD's one-time correction approach aims to offer the potential for durable functional improvement with lower doses of AAV. In consideration of the data, the high unmet need of those afflicted with DMD due to limited treatment options, and the established regulatory support and guidance within the FDA, we have prioritized this program to be our second wholly owned program with a target IND and/or clinical trial application (CTA) in 2025,' continued Mr. Amoroso. 'This reinforces our commitment to delivering transformative therapies in genetic diseases with the highest unmet need and driving near and long-term value while being prudent stewards of capital.'
Wholly Owned Portfolio
PBGENE-HBV (Viral Elimination Program): PBGENE-HBV is Precision's wholly owned in vivo gene editing program under investigation in a global first-in-human clinical trial, which is designed to be a potentially curative treatment for chronic Hepatitis B infection. PBGENE-HBV is the first and only potentially curative gene editing program to enter the clinic that is specifically designed to eliminate cccDNA and inactivate integrated HBV DNA, the root cause chronic Hepatitis B. The ELIMINATE-B trial is investigating PBGENE-HBV at multiple ascending dose levels with three dose administrations per dose level in patients with chronic Hepatitis B.
In February 2025, Precision announced initial results from the first administration of PBGENE-HBV in cohort 1, the lowest dose level of the ELIMINATE-B trial. PBGENE-HBV was safe and well tolerated in all three participants in cohort 1 after the first administration of a 0.2 mg/kg dose. In addition to safety, PBGENE-HBV demonstrated a substantial reduction in Hepatitis B surface antigen (HBsAg) in two of the three participants following the first administration at the lowest dose level.
In March 2025, the FDA cleared PBGENE-HBV to commence Phase 1 clinical trials in the U.S and in April 2025, the FDA granted Fast Track designation to PBGENE-HBV for chronic Hepatitis B. Throughout 2025, the Company plans to share updates on full cohorts including antiviral efficacy at different dose levels as each cohort is completed following three dose administrations and appropriate follow up. Also, in April 2025, the U.K. Medicines and Healthcare products Regulatory Agency cleared PGENE-HBV for Phase 1 trial making it the fifth country to clear a CTA or IND for PBGENE-HBV.
On May 8, 2025, Precision presented initial safety data for PBGENE-HBV at the European Association for the Study of the Liver Congress (EASL), which indicated translation of PBGENE-HBV nonclinical pharmacokinetic and safety data from non-human primates into the clinic. These data support pre-planned repeat dosing as well as dose escalation of PBGENE-HBV with the goal of moving appropriate dose and schedule into Phase 2 expansion.
PBGENE-DMD (Muscle Targeted Excision Program): PBGENE-DMD is Precision's development program for the treatment of DMD. DMD is a genetic disease caused by mutations in the dystrophin gene that prevent production of the dystrophin protein and affects approximately 15,000 patients in the U.S. alone. There are currently no approved therapies that can drive durable and significant functional improvements over time. PBGENE-DMD is designed to improve function over time and addresses more than 60% of patients afflicted with DMD by employing two complementary ARCUS nucleases delivered in a single AAV to excise exons 45-55 of the dystrophin gene with the aim of restoring a near-full length functional dystrophin protein within the body that more closely resembles normal dystrophin as opposed to synthetic, truncated dystrophin approaches with minimal functional benefit.
In preclinical data presented at the muscular Dystrophy Association (MDA) in March 2025 and additional new data presented at the American Society of Gene and Cell Therapy (ASGCT) on May 14, 2025, PBGENE-DMD demonstrated the ability to target key muscle types involved in the progression of DMD and significant, durable functional improvement in a humanized DMD mouse model. PBGENE-DMD restored the body's ability to produce a near full length functional dystrophin protein across multiple muscles, including cardiac tissue and various key skeletal muscle groups. In addition, PBGENE-DMD edited satellite muscle stem cells, believed to be critical for long-term durability and sustained functional improvement.
Based on these compelling data, the significant unmet need in DMD, and the clear regulatory guidance established for new therapeutics for DMD, Precision believes that PBGENE-DMD holds significant potential for the majority of patients with DMD. As a result, Precision is prioritizing and accelerating the development of PBGENE-DMD as its second wholly owned clinical program and targets filing an IND and/or CTA for PBGENE-DMD in 2025 with clinical data expected in 2026.
PBGENE-3243 (Mutant Mitochondrial DNA Elimination Program): PBGENE-3243 is a first-of-its-kind potential treatment for m.3243-associated mitochondrial disease that is designed to specifically target and eliminate mutant m.3243G mitochondrial DNA, thereby eliminating the root cause of the disease. Currently, there are no curative treatments for m.3243-associated mitochondrial disease, which affects approximately 20,000 people in the U.S. alone and an even larger prevalent population globally. PBGENE-3243 is designed to alleviate muscular myopathy symptoms, providing a significant quality of life and functional improvement for patients.
New preclinical data presented at ASGCT on May 14, 2025, highlight the ability of an ARCUS nuclease to eliminate mutant mitochondrial DNA and achieve therapeutically meaningful heteroplasmy shifts in vivo. Reductions of mutant mtDNA exceed the baseline cited in the literature to be sufficient to alleviate the clinical symptoms in patients with m.3243-associated disease.
To accelerate development of PBGENE-DMD and maintain operational capability to deliver PBGENE-HBV and PBGENE-DMD data through Phase 1 clinical results, Precision plans to pause development of PBGENE-3243 and will stage future development of PBGENE-3243 alone or with partners following completion of the Phase 1 ELIMINATE-B HBV trial and after the PBGENE-DMD program reaches the clinic.
Partnered Programs:
iECURE-OTC (Gene Insertion Program): Led by iECURE, ECUR-506 is an ARCUS-mediated in vivo gene editing program currently in a first-in-human Phase 1/2 trial (OTC-HOPE) evaluating ECUR-506 as a potential treatment for neonatal onset ornithine transcarbamylase (OTC) deficiency. In January 2025, iECURE reported clinical efficacy and safety data in the first patient dosed showing a complete clinical response from three months post-exposure to the end of study at six months, as defined by the study protocol. The patient is now more than one year old and is eating age-appropriate levels of protein for a child of this age. Clinical data from the first patient in the ongoing OTC-HOPE trial was presented at the 2025 ACMG Annual Clinical Genetics Meeting in March 2025 and additional data has been accepted for presentation at ASGCT 2025.
The OTC-HOPE study is ongoing in the U.K., the U.S., Australia, and Spain, and iECURE expects to complete enrollment in 2025 and anticipates complete data from the trial in the first half of 2026.
PBGENE-NVS (Gene Insertion Program): Precision continues to advance its gene editing program with Novartis to develop a custom ARCUS nuclease for patients with hemoglobinopathies, such as sickle cell disease and beta thalassemia. The collaborative intent is to insert, in vivo, a therapeutic transgene as a potential one-time transformative treatment administered directly to the patient to overcome disparities in patient access to treatment with other therapeutic technologies, including those that are targeting an ex vivo gene editing approach.
Quarter Ended March 31, 2025 Financial Results:
Cash, Cash Equivalents, and Restricted Cash: As of March 31, 2025, Precision had approximately $100 million in cash, cash equivalents, and restricted cash. The Company expects that existing cash and cash equivalents, potential near-term cash from CAR T transactions, along with expected operational receipts, continued fiscal and operating discipline, and availability of Precision's at-the-market (ATM) facility to extend Precision's cash runway into the second half of 2026. Based on its expected cash runway, Precision believes it is sufficiently capitalized to advance its two lead wholly owned programs, PBGENE-HBV and PBGENE-DMD through Phase 1 data readouts.
Revenues: Total revenues for the quarter ended March 31, 2025, were less than $0.1 million, as compared to $17.6 million for the quarter ended March 31, 2024. The decrease of $17.6 million was due to revenue recognized from TG Therapeutics and Caribou Biosciences agreements in the quarter ended March 31, 2024, a decrease in the revenue recognized under the Prevail agreement following conclusion of the collaboration in April 2024, and a decrease in revenue recognized under the Novartis Agreement as Precision nears completion of its pre-clinical workplan.
Research and Development Expenses: Research and development expenses were $13.6 million for the quarter ended March 31, 2025, as compared to $13.3 million for the quarter ended March 31, 2024. The increase of $0.3 million was primarily due to an increase in direct expense for PBGENE-DMD as the program advances towards the clinic.
General and Administrative Expenses: General and administrative expenses were $8.6 million for the quarter ended March 31, 2025, as compared to $8.4 million for the quarter ended March 31, 2024. The increase of $0.2 million was primarily due to employee-related costs, partially offset by decreases in depreciation and amortization expense as well as taxes and insurance.
Net Loss: Net loss was $20.6 million, or $(2.21) per share (basic and diluted), for the quarter ended March 31, 2025. Net income was $8.6 million, or $1.70 per share (basic and diluted), for the quarter ended March 31, 2024.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS ® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Precision's two lead programs, PBGENE-HBV, for chronic Hepatitis B, and PBGENE-DMD, for Duchenne muscular dystrophy are focused on areas with large patient populations with high unmet need. Using ARCUS, the Company's pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
The ARCUS ® platform is being used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into a gene to cause expression/add function), elimination (removing a genome e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV).
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the potential of PBGENE-DMD to be a first-in-class in vivo gene editing approach addressing the majority of DMD patients; the safety data and antiviral activity established after the administrations of PBGENE-HBV; translation of results in preclinical studies of ARCUS nucleases to clinical studies in humans; the preclinical and clinical development and demonstrated, potential and expected safety, efficacy and benefit of PBGENE-HBV and PBGENE-DMD, as well as our other product candidates and those being developed by partners; the unique design of PBGENE-HBV to eliminate cccDNA and inactivate integrated HBV DNA with high specificity, potentially leading to functional cures; the expected timing and opportunities of regulatory processes (including filings such as INDs or CTAs for PBGENE-HBV and PBGENE-DMD and the acceptance of these filings by regulatory agencies); the suitability of PBGENE-HBV for the treatment of hepatitis and the targeting of the root cause of the disease; the key advantages of ARCUS and its key capabilities and differentiating characteristics; expectations about operational initiatives, strategies, further development, or timing of additional updates or data releases of PBGENE-HBV and PBGENE-DMD; plans to provide additional administrations of PBGENE-HBV at the first dose level; plans to escalate to higher dose levels and next cohorts in the ELIMINATE-B clinical trial; expansion of the ELIMINATE-B clinical trial to the United States and United Kingdom; expectations around accelerating the PBGENE-DMD program; the design of PBGENE-DMD to improve function over time and address more than 60% of patients with DMD; the potential for PBGENE-DMD to provide durable functional improvement with a one time lower dose of AAV; the complete enrollment of the OTC-HOPE study in the U.S., the U.K., Australia, and Spain and timing of full data from the trial in the first half of 2026; expectations and announcements about achievement of key milestones; our expected cash runway and the sufficiency of our cash runway extending into the second half of 2026 to advance PBGENE-HBV and PBGENE-DMD through Phase 1 data readouts; and the staged development of PBGENE-3243 alone or with partners following completion of the Phase 1 ELIMINATE-B trial and after the PBGENE-DMD program reaches the clinic. In some cases, you can identify forward-looking statements by terms such as 'aim,' 'anticipate,' 'approach,' 'believe,' 'contemplate,' 'could,' 'design,' 'designed,' 'estimate,' 'expect,' 'goal,' 'intend,' 'look,' 'may,' 'mission,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'pursue,' 'should,' 'strive,' 'suggest,' 'target,' 'will,' 'would,' or the negative thereof and similar words and expressions.
Forward-looking statements are based on management's current expectations, beliefs, and assumptions and on information currently available to us. These statements are neither promises nor guarantees, and involve a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to, our ability to become profitable; our ability to procure sufficient funding to advance our programs; risks associated with our capital requirements, anticipated cash runway, requirements under our current debt instruments and effects of restrictions thereunder, including our ability to raise additional capital due to market conditions and/or our market capitalization; our operating expenses and our ability to predict what those expenses will be; our limited operating history; the progression and success of our programs and product candidates in which we expend our resources; our limited ability or inability to assess the safety and efficacy of our product candidates; the risk that other genome-editing technologies may provide significant advantages over our ARCUS technology; our dependence on our ARCUS technology; the initiation, cost, timing, progress, achievement of milestones and results of research and development activities and preclinical and clinical studies, including clinical trial and investigational new drug applications; public perception about genome editing technology and its applications; competition in the genome editing, biopharmaceutical, and biotechnology fields; our or our collaborators' or other licensees' ability to identify, develop and commercialize product candidates; pending and potential product liability lawsuits and penalties against us or our collaborators or other licensees related to our technology and our product candidates; the U.S. and foreign regulatory landscape applicable to our and our collaborators' or other licensees' development of product candidates; our or our collaborators' or other licensees' ability to advance product candidates into, and successfully design, implement and complete, clinical trials; potential manufacturing problems associated with the development or commercialization of any of our product candidates; delays or difficulties in our and our collaborators' and other licensees' ability to enroll patients; changes in interim 'top-line' and initial data that we announce or publish; if our product candidates do not work as intended or cause undesirable side effects; risks associated with applicable healthcare, data protection, privacy and security regulations and our compliance therewith; our or our licensees' ability to obtain orphan drug designation or fast track designation for our product candidates or to realize the expected benefits of these designations; our or our collaborators' or other licensees' ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product candidate; the rate and degree of market acceptance of any of our product candidates; our ability to effectively manage the growth of our operations; our ability to attract, retain, and motivate executives and personnel; effects of system failures and security breaches; insurance expenses and exposure to uninsured liabilities; effects of tax rules; effects of any pandemic, epidemic, or outbreak of an infectious disease; the success of our existing collaboration and other license agreements, and our ability to enter into new collaboration arrangements; our current and future relationships with and reliance on third parties including suppliers and manufacturers; our ability to obtain and maintain intellectual property protection for our technology and any of our product candidates; potential litigation relating to infringement or misappropriation of intellectual property rights; effects of natural and manmade disasters, public health emergencies and other natural catastrophic events; effects of sustained inflation, supply chain disruptions and major central bank policy actions; market and economic conditions; risks related to ownership of our common stock, including fluctuations in our stock price; our ability to meet the requirements of and maintain listing of our common stock on Nasdaq or other public stock exchanges; and other important factors discussed under the caption 'Risk Factors' in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, as any such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC's website at www.sec.gov and the Investors page of our website under SEC Filings at investor.precisionbiosciences.com.
All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Precision Biosciences, Inc.
Balance Sheets Data
(In thousands, except share amounts)
March 31, 2025 December 31, 2024
Cash, cash equivalents, and restricted cash
$
99,789
$
108,468
Working capital
69,710
80,009
Total assets
124,411
136,388
Total liabilities
75,074
79,995
Total stockholders' equity
$
49,337
$
56,393
Common stock outstanding
10,548,852
8,202,715
Expand
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
OTC Markets Group Welcomes First Phosphate Corp. to OTCQX
NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced First Phosphate Corp. (CSE: PHOS; OTCQX: FRSPF), an igneous phosphate mineral development company for the LFP battery industry, has qualified to trade on the OTCQX® Best Market. First Phosphate Corp. upgraded to OTCQX from the OTCQB® Venture Market. First Phosphate Corp. begins trading today on OTCQX under the symbol 'FRSPF.' U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on The OTCQX Market is designed for established, investor-focused U.S. and international companies. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. Graduating to the OTCQX Market from the OTCQB Market marks an important milestone for companies, enabling them to demonstrate their qualifications and build visibility among U.S. investors. About First Phosphate Phosphate Corp. is a mineral development company fully dedicated to extracting and purifying phosphate for the production of cathode active material for the Lithium Iron Phosphate ("LFP") battery industry. First Phosphate is committed to producing at high purity level, in responsible manner, and with low anticipated carbon footprint. First Phosphate plans to vertically integrate from mine source directly into the supply chains of major North American LFP battery producers that require battery grade LFP cathode active material emanating from a consistent and secure supply source. About OTC Markets Group Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our public markets: OTCQX® Best Market, OTCQB® Venture Market, OTCID™ Basic Market and Pink Limited™ Market. Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets. OTC Link ATS, OTC Link ECN, OTC Link NQB, and MOON ATS™ are each SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC. To learn more about how we create better informed and more efficient markets, visit Subscribe to the OTC Markets RSS Feed Media Contact:OTC Markets Group Inc., +1 (212) 896-4428, media@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
21 minutes ago
- Business Wire
Ops Powerhouse Claire Alexander Launches Precision-Built Platform for Streamlined Operations, Scale and Growth
SEATTLE--(BUSINESS WIRE)--A new era of business building begins with the official launch of The Arch's Anvil, an operations and growth platform created by financial services industry veteran Claire Alexander (Alexander). Alexander aims to help service-based firms transform big visions into high-functioning businesses. Developed through years of in-the-trenches experience in financial services, insurance, and real estate, The Arch's Anvil brings a streamlined, centralized, and personalized approach to structuring and strengthening client-service operations, making it a powerful new tool for financial advisors, entrepreneurs, attorneys, CPAs, and other small business owners serving individual clients in service-based professions. We provide tools and structure, built collaboratively in just 10 weeks to help business owners bring their vision to life, allowing them to spend less time on administrative friction and more time focusing on what matters to their clients and their growth. Share Alexander's grounding principle for The Arch's Anvil is this: Intentional business owners – and even accidental entrepreneurs – are the architects of their future. The platform positions itself as the essential tool, or 'anvil,' to shape that vision into sustainable success. Having spent over a decade building systems, processes, and teams within the financial services industry, Alexander gained significant expertise. This included scaling internal operations at a wealth advisory firm to $3.5 billion in assets through various transitions like mergers, acquisitions, affiliations, and succession, which ultimately highlighted for her the pervasive operational gaps facing not only financial advisory firms but also service providers in adjacent professions. Many of the available resources were either disconnected, overly technical, or not tailored to the boutique service businesses that prioritize trust and tangible client outcomes. 'At The Arch's Anvil, we don't just advise; we're in the trenches with you, transforming your company vision into a powerful, client-facing service system,' noted Founder Claire Alexander. 'We deliver everything from custom email sequences and branded templates to the robust back-end tech stack, ensuring a seamless, hands-off experience for your team. We tackle the operational 'craziness'—from onboarding and training to workflow design—freeing up critical time and eliminating bottlenecks.' 'Our ultimate goal is to provide the tools and structure, built collaboratively in just 10 weeks, so you can bring your vision to life, faster, and without the piecemeal struggle,' Alexander added. 'This helps business owners spend less time on administrative friction and more time focusing on what matters to their clients and their growth. The additional time we'll spend together 1:1 is also a key part of the value proposition – and seeing the immediate interest and demand for this work has been energizing. I look forward to partnering with more right-fit clients to create meaningful results and invite them to connect with me through my website.' ELIMINATING OPERATIONAL FRICTION FOR BUSINESS OWNERS The platform's core function is to help professionals, such as financial advisors, CPAs, attorneys, real estate agents, insurance professionals, and trusted consultants, create a more manageable and efficient workflow. It's particularly tailored for firms that work with individual clients and require robust, repeatable processes to reliably deliver high-quality service. The Arch's Anvil addresses key pain points for service-based firms by centralizing communications, integrating business tools, standardizing workflows, improving transparency and accountability, easing onboarding, minimizing administrative burdens, and enabling firms to maintain organized and accessible records — all designed for efficient, client-focused operations. The platform is both tailored and flexible: The basic structure centers around a secure, centralized digital dashboard that serves as the operational hub for service-based businesses. When users log in, they are presented with a straightforward interface that organizes all their business resources, project deliverables, documents, and workflow materials, making this essential information easily accessible and all in one place. The design is intended to eliminate fragmented processes, eradicating the need to search through emails or use disconnected platforms to find important information. 'Claire took me through The Arch's Anvil platform, and I was truly impressed. Any business owner, especially those struggling with small business complexities like mine, would benefit from this solution,' said Marie Swift, Founder of Impact Communications and Host of Swift Chats in the Financial Services Industry, a video interview and podcast series. 'Claire's expertise in financial services, as well as her experience in real estate and insurance, shines through in how versatile and practical the platform is. It's clear that The Arch's Anvil can make operations much more streamlined and manageable for advisors, service firms, and anyone who needs an organized approach to serving clients.' View or listen to the Swift Chat interview with Claire Alexander here: 'I've had the privilege of working directly with Claire, and she is one of the most gifted operations professionals I've encountered. Claire brings structure, clarity, and momentum to every business she touches. Her ability to transform complexity into streamlined systems is exceptional,' said Scott Danner, Entrepreneur, M&A Strategist, Author, and Host of The High Performance Life Podcast. 'I fully support the launch of The Arch's Anvil and look forward to seeing the impact she will continue to make for service-based businesses across the country.' ABOUT CLAIRE ALEXANDER Claire Alexander is a seasoned operations leader with nearly a decade as a licensed financial advisor and insurance professional, distinguished by her hands-on experience in the operational trenches of thriving advisory firms. She was instrumental in scaling a financial advisory practice by building robust internal systems that contributed to $3 billion in assets under management growth in just four years. Alexander's expertise is comprehensive; she has led or managed every key department within a company, from marketing strategy and HR systems to meticulous bookkeeping, seamless client onboarding, rigorous compliance, and effective employee training. Her operational leadership extends beyond financial services to include managing multi-million-dollar construction projects, crafting systems for real estate and property management companies, and overseeing the complex operations of over 100 contractors and employees. Having personally built and scaled operational structures for multiple businesses, Alexander champions the conviction that true, lasting efficiency forms the bedrock of unstoppable growth. Through The Arch's Anvil, she brings this broad and practical expertise to service-based professionals seeking to transform their vision into a reliable, scalable business reality. ABOUT THE ARCH'S ANVIL The Arch's Anvil is a business operations platform built for service-based professionals such as financial advisors, CPAs, attorneys, real estate agents, insurance professionals, and trusted consultants — as well as other growth-minded business owners seeking to streamline client service workflows, strengthen internal operations, and achieve scalable growth. At its core is a centralized digital dashboard, allowing users to log in and access all operational resources, project deliverables, and essential documents in one secure location, replacing fragmented communications and disjointed systems with organized, accessible structure. The platform is shaped by direct industry experience and offers personalized setup and guidance to fit the unique needs of different client-focused businesses, ensuring workflows are both consistent and adaptable. The Arch's Anvil addresses challenges such as maintaining organized records, integrating tools, standardizing processes, and onboarding efficiently, ultimately enabling firms to reduce administrative friction and concentrate on delivering high-quality service. What truly sets The Arch's Anvil apart is the direct, hands-on support clients receive. Clients have direct access to its founder and benefit from weekly 1:1 strategy calls. During these calls, The Arch's Anvil breaks down the specific details of a company and focuses on the week's projects, ensuring their vision comes to life with dedicated guidance.
Business Wire
21 minutes ago
- Business Wire
DCL Logistics Launches SelectShip, an AI-Powered Shipping Engine Built for Peak Season Performance and Beyond
SAN FRANCISCO--(BUSINESS WIRE)-- DCL Logistics, a leading fulfillment partner for modern ecommerce brands, today announced the launch of SelectShip, an AI-powered shipping engine already being used by brands like Canopy, Cure Hydration, and NuFace to automate parcel decisions, reduce unforeseen delivery costs, and use real-time shipping market data to meet rising customer expectations without adding operational overhead. Brands are locking in logistics strategies for Q4, a season where fulfillment execution can make or break revenue. This year, a perfect storm of tariff uncertainty, rising supply chain costs, and heightened consumer expectations has put parcel operations under pressure. Most ecommerce teams are using static, outdated logic to manage a dynamic industry of fragmented carrier networks, volatile fees, and thinner margins than ever before—without the infrastructure to adapt in real time. DCL Logistics built SelectShip in response to the rising complexity of parcel delivery and the growing pressure on fulfillment teams to do more with less. The fully managed, AI-powered system automates thousands of shipping decisions in real time, optimizing for speed, cost, and reliability for each order. Embedded within DCL's fulfillment platform, SelectShip requires no new tools, dashboards, or configuration from the customer. 'Parcel delivery has become one of the most visible and unforgiving parts of the ecommerce experience,' said Dave Tu, President of DCL Logistics. 'SelectShip reflects our belief that fulfillment partners shouldn't just provide software. They should own the systems and execution that brands can rely on. This is not another tool. It's an intelligent system, fully operated by our team, that turns shipping from a liability into a competitive edge.' Already in Market, Already Delivering SelectShip is already live with leading ecommerce brands and delivering measurable improvements across cost, speed, and customer experience. Built to operate behind the scenes, the platform enables fast, intelligent shipping decisions without adding operational overhead. Operational Results to Date: Shipping costs have decreased by 12 to 19% on average Transit times from two key facilities improved from 3.1 to 2.3 days using standard shipping One-third of orders are now arriving next day Delivery area surcharges have been avoided in over 95% of cases 55 to 60% of shipments include photo proof of delivery for added transparency 'DCL is taking a forward-thinking approach by embedding real-time shipping intelligence directly into their fulfillment operations,' said Jason Murray, CEO and Co-Founder at Shipium. 'SelectShip reflects what modern logistics infrastructure should look like. Brands get adaptive, AI-powered performance without the overhead of managing rules, carriers, or disconnected tools.' Built to Operate, Not Just Inform Most 3PLs rely on outdated systems with static logic that only take into account a few of many thousands of critical shipping variables. DCL takes a different approach. SelectShip is a dynamic tool that leverages machine learning to evaluate thousands of critical variables in real time, ensuring every package is automatically optimized for speed, reliability and cost. It's fully managed and embedded within DCL's fulfillment stack, with routing intelligence powered by Shipium and execution handled entirely by DCL's transportation team. Core Features Include: AI-optimized routing based on real-time data across billions of network data points Automated carrier and service selection for every order at the time of manifest Built-in compliance and label validation safeguards Calculates for the all-in cost, not just the base rate – including all extra fees like fuel, surcharges and more Transparent invoicing that eliminates surprise fees Fast onboarding, with most brands live in under three weeks Seamless integration with DCL's eFactory platform, no extra tools required SelectShip builds on DCL's commitment to owning fulfillment end-to-end. It delivers intelligent, embedded infrastructure that adapts to each order in real time, without requiring customer-side complexity. This launch marks a broader shift in how DCL supports growth-stage brands: by turning shipping into a system, not a set of decisions. To learn more about SelectShip and how it integrates with DCL's fulfillment services, visit: About DCL Logistics DCL Logistics is a modern third-party logistics (3PL) provider that combines operational expertise with a technology-forward approach. For over 40 years, DCL has helped high-growth brands scale by delivering fast, flexible fulfillment solutions backed by high-touch customer service. Learn more at About Shipium Shipium is an end-to-end shipping platform that helps modern operators improve speed and reliability while reducing cost. Built by the team behind Amazon's shipping stack, Shipium brings enterprise-grade delivery performance through an API-first platform. Learn more at
